Key Segmentation:
By Synthesis Method
-
Solid-Phase Peptide Synthesis (SPPS)
-
Liquid-Phase Peptide Synthesis (LPPS)
-
Hybrid & Recombinant Synthesis
By Scale of Operation
-
Pre-Clinical
-
Clinical
-
Commercial
By Therapeutic Area
-
Metabolic Disorders
-
Oncology
-
Cardiovascular Diseases
-
Infectious Diseases
-
Other Therapeutic Areas
By Product Type
-
Innovator Peptides
-
Generic Peptides
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Synthesis Method X Scale of Operation)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Bachem Holding AG, PolyPeptide Group AG, CordenPharma International, Lonza Group AG, and WuXi AppTec Co., Ltd., among others.
Key opportunities include greener hybrid and liquid-phase synthesis routes, regional capacity diversification and onshoring, and rising demand from oral peptides, peptide-drug conjugates, radioligands and generic GLP-1 programs.
The primary growth factor is the surge in GLP-1 and related incretin therapies for diabetes and obesity, combined with sponsors' growing reliance on specialist contract manufacturers for large-scale, complex peptide synthesis.
By synthesis method, the Solid-Phase Peptide Synthesis (SPPS) segment dominates the Peptide API CMO Market with approximately 57.26% share in 2025.
North America dominates the Peptide API CMO Market with approximately 41.37% share in 2025, while Asia-Pacific is the fastest-growing region at a CAGR of 11.26% from 2026-2035.
